Financial Performance
5Y price score: (38)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: (28.6)%
US$ Per
Share
By default your notes are visible only to you.
14.0
52-week range
21.8
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
5.7 %
Dividend Yield TTM
4.3 %
Market cap $
$ 36,864
Price / Earnings TTM
22.1
Price / Book TTM
3.5
PEG TTM
0.5
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(7.8) %
(21.1) %
(28.6) %
Free cash flow per share growth
28.9 %
(46.6) %
-
Earnings per share growth
40.7 %
261.7 %
-
Founded: 2,022
Employees: 22,000
Business Summary:
Latest Earnings Call Takeaways
2025 Q2 (Aug 7, 2025)
1) Leadership Changes and Strategic Focus - Kirk Perry has stepped in as interim CEO, emphasizing the need for urgency and a strategic review of alternatives to unlock shareholder value. - The Board has initiated a comprehensive review of the brand portfolio and operational strategies to enhance performance. - New leadership appointments, including Amit Banati as CFO and Andy Dasgupta as head of Asia Pacific, aim to strengthen capabilities and drive growth.
2) Financial Performance Overview - Kenvue reported a 4.2% decline in organic sales for Q2 2025, with consumption growth outpacing this decline across all segments. - Adjusted operating margin contracted 10 basis points to 22.7%, with adjusted diluted EPS at $0.29, down from $0.32 YoY. - The Self Care segment faced significant challenges due to unfavorable seasonal dynamics, with organic sales down 5.9%.
3) Segment Performance Insights - Self Care: Despite a decline in organic sales, ZYRTEC gained market share and household penetration. The segment's performance was impacted by weak seasonal demand. - Skin Health and Beauty: Organic sales decreased 3.7%, but there was sequential improvement in consumption, particularly for Neutrogena Face. - Essential Health: Organic sales down 2.4%, with a focus on increasing household penetration for Listerine through new campaigns.
4) Operational Challenges and Future Plans - Complexity in the organization has been identified as a barrier to agility and performance; efforts will focus on reducing SKUs and simplifying operations. - The leadership team is prioritizing flawless execution and a consumer-centric approach to drive market share. - The company is revising its guidance for 2025, expecting low single-digit declines in organic sales, influenced by macroeconomic factors and inventory dynamics.
5) Guidance and Outlook - The revised outlook for 2025 anticipates continued challenges, with adjusted diluted EPS projected between $1.00 and $1.05. - The company is committed to improving operational performance and financial results, with a focus on strategic investments that yield higher returns. - Additional details on the strategic review and operational improvements were not provided, leaving some uncertainty regarding specific actions and timelines.
Bottom line: Kenvue is undergoing significant leadership changes and strategic reviews to address operational complexities and improve financial performance. While recent results have been disappointing, the focus on core brands and consumer-centric strategies aims to unlock potential and drive shareholder value in the long term.
Annual Reports, Presentations And IR Contacts
Go to the websiteKenvue — Financial Overview, Stock Price, Market Cap
Kenvue is a company. Founded in 2022. As of August 14, 2026, the company's market capitalization is $36864166426 with a current stock price of $19.20.